<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543085</url>
  </required_header>
  <id_info>
    <org_study_id>PT1710001</org_study_id>
    <nct_id>NCT03543085</nct_id>
  </id_info>
  <brief_title>Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain</brief_title>
  <official_title>A Single-arm, Open Label, Single Center, Prospective Study of Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GiMer Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GiMer Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm, open label, single center to confirm the&#xD;
      effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in&#xD;
      patients with chronic back pain or lower limb pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, open label, single center to confirm the&#xD;
      effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in&#xD;
      patients with chronic back pain or lower limb pain. The trial length is 14 days. Patients&#xD;
      will be given ultrahigh frequency pulse stimulation, up to 3 times in every 24 hours, and VAS&#xD;
      will be obtained at least once a day. Compared to previous study conducted last year, patient&#xD;
      can now have two lead implant sites for different pain locations. The electrode implantation&#xD;
      site will be epidural space instead of Dorsal Root Ganglion (DRG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">October 23, 2018</completion_date>
  <primary_completion_date type="Actual">October 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Score From Baseline to Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Record Incidence of Adverse Events</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Brief Pain Inventory (BPI)</measure>
    <time_frame>14 days</time_frame>
    <description>The change from baseline in functionality using the BPI evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stimulation-induced Paresthesia</measure>
    <time_frame>14 days</time_frame>
    <description>To determine the presence or absence of stimulation-induced paresthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Medication Consumption</measure>
    <time_frame>14 days</time_frame>
    <description>Amount of pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Low Back Pain Disability Questionnaire (ODI)</measure>
    <time_frame>14 days</time_frame>
    <description>The change from baseline in functionality using the ODI evaluations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pain, Chronic</condition>
  <condition>Pain, Back</condition>
  <condition>Pain, Radiating</condition>
  <arm_group>
    <arm_group_label>Ultrahigh Frequency (500 KHz) Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GiMer Medical MN 1000 External Stimulator</intervention_name>
    <description>Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
    <arm_group_label>Ultrahigh Frequency (500 KHz) Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≧20 and ≦75&#xD;
&#xD;
          2. Have a symptom of back or lower limb pain with a diagnosis related to spinal lesion,&#xD;
             herniated disc, nerve injury, stenosis, failed back surgery syndrome (FBSS), complex&#xD;
             regional pain syndrome (CRPS) or ischemic lower limb pain and have pain history of &gt;6&#xD;
             months.&#xD;
&#xD;
          3. Have an average pain score &gt;5 by Visual Analogue Scale (VAS) on inclusion.&#xD;
&#xD;
          4. Has failed to achieve adequate pain relief from prior pharmacologic treatments.&#xD;
&#xD;
          5. In the judgement of the investigator, the subject is an appropriate candidate for the&#xD;
             trial procedure.&#xD;
&#xD;
          6. The subject is willing and able to comply with the procedure and requirements of this&#xD;
             trial.&#xD;
&#xD;
          7. The participant is able to understand and provide informed consent, and has signed&#xD;
             their written informed consent in accordance with Institutional Review Board (IRB)&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have evidence of a mental or psychological condition that affects pain perception and&#xD;
             has difficulty/disability performing objective pain assessment, or have previously&#xD;
             failed mental or psychological assessments administered by a psychiatrist that may be&#xD;
             deemed to indicate the subject's lack of suitability for participation in this study.&#xD;
&#xD;
          2. Subject has exhibited unstable pain condition within the past 30 days as interviewed&#xD;
             by Investigator.&#xD;
&#xD;
          3. Be on anticoagulant medication with International Normalized Ratio (INR) &gt;1.5 or&#xD;
             platelet count less than 100,000/μL, peripheral vascular diseases (PVDs), visceral&#xD;
             pain or uncontrolled Diabetes mellitus (DM).&#xD;
&#xD;
          4. Has had corticosteroid therapy at an intended site of stimulation within the past 30&#xD;
             days.&#xD;
&#xD;
          5. Pain medication(s) dosages(s) are not stable for at least 30 days at investigator's&#xD;
             discretion.&#xD;
&#xD;
          6. Currently has an active implantable device including International Classification of&#xD;
             Diseases (ICD), pacemaker, spinal cord stimulator or intrathecal drug pump or subject&#xD;
             requires magnetic resonance imaging (MRIs) or diathermy.&#xD;
&#xD;
          7. Have a current diagnosis of cancer with active symptoms.&#xD;
&#xD;
          8. Have a known terminal illness with life expectancy less than one year.&#xD;
&#xD;
          9. Have a systematic or local infection, which may increase study risk.&#xD;
&#xD;
         10. Currently has an indwelling device that may pose an increased risk of infection.&#xD;
&#xD;
         11. Be pregnant or breast feeding.&#xD;
&#xD;
         12. Have a medical history of drug or alcohol addiction within the past 2 years.&#xD;
&#xD;
         13. Participation in any investigational study in the last 30 days or current enrollment&#xD;
             in any trial.&#xD;
&#xD;
         14. Be currently involved in an injury claim law suit or medically related litigation,&#xD;
             including workers compensation.&#xD;
&#xD;
         15. Be a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <results_first_submitted>June 4, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03543085/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ultrahigh Frequency (500 KHz) Stimulation</title>
          <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ultrahigh Frequency (500 KHz) Stimulation</title>
          <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="24.9" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Score From Baseline to Day 14</title>
        <description>To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency (500 KHz) Stimulation</title>
            <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Score From Baseline to Day 14</title>
          <description>To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Record Incidence of Adverse Events</title>
        <description>To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency (500 KHz) Stimulation</title>
            <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Record Incidence of Adverse Events</title>
          <description>To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Brief Pain Inventory (BPI)</title>
        <description>The change from baseline in functionality using the BPI evaluations</description>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stimulation-induced Paresthesia</title>
        <description>To determine the presence or absence of stimulation-induced paresthesia.</description>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Medication Consumption</title>
        <description>Amount of pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline</description>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Low Back Pain Disability Questionnaire (ODI)</title>
        <description>The change from baseline in functionality using the ODI evaluations</description>
        <time_frame>14 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days from baseline</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ultrahigh Frequency (500 KHz) Stimulation</title>
          <description>This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yeong-Ray Wen (Department of Anaesthesia)</name_or_title>
      <organization>China Medical University Hospital (in Taiwan)</organization>
      <phone>+886 4 2205-2121</phone>
      <email>yray.wen@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

